Madam Chair, I would also like to simply add, in the minute that remains to me, that department officials are conducting a review of the Canadian adverse drug reaction reporting system, which will examine the barriers to reporting on alternate strategies to increase reporting rates. The new Marketed Health Products Directorate will draw on additional advice through increased emphasis on involvement of external experts and stakeholder advice and input concerning marketed health product safety and effectiveness.
In the few seconds I have left, I would like to add that the department has worked very hard, not only to respond, but also to anticipate what could happen during such unfortunate circumstances as those faced by Toronto, other parts of Canada, and other parts of the world. The Department of Health is ready—it has been and it still is—to protect the lives of Canadians.